NASDAQ Healthcare Biotechnology XOMA

XOMA Royalty Corp.

$ 41.89 0.41 %

XOMA Royalty Corp. functions as a specialist in aggregating biotechnology royalties, with its operations extending across Europe, the United States, and the Asia Pacific region. The company is dedicated to fostering advancements in human health by collaborating with biotechnology firms. Its core business model involves acquiring the anticipated future economic benefits, such as royalties and milestone payments, associated with pre-market therapeutic candidates that have already been licensed to pharmaceutical or biotechnology firms. The firm focuses its investments on early to mid-stage clinical assets, typically those in Phase 1 and 2 trials, selected for their robust commercial potential and because they are licensed to development partners. Its extensive portfolio currently encompasses around 70 distinct assets. The parent company, XOMA Corporation, established in 1981, has its main office in Emeryville, California.

CEO: Owen Hughes Jr. - https://www.xoma.com

Summary 30-Y Financials Dividend Analyst Key metrics Ownership / Senat
Price objectif

$44.5 6.23 %

Recommandation

Buy

DCF

$ -50.89

Loading data...

XOMA vs S&P500

Loading data...

No data available.

Quick ratio

3.59

suggests a healthy liquidity position, showing that the company can likely meet its short-term obligations.

P/E ratio

26.68

is considered reasonable, suggesting that the company has a valuation in line with its current profits.

EPS

1.57

is the net profit of a company divided by the number of outstanding shares, indicating the profit earned per share.

ROE

30.21 %

is generally considered excellent, indicating that the company is generating strong profits with its equity.

ROIC

1.94 %

does not generate enough return to cover its financing costs, which indicates value destruction and may pose long-term profitability issues.

WACC

8.48

is a company's average cost of capital, weighted by the proportion of debt and equity in its financing. It represents the minimum return the company must generate to satisfy its investors.

Debt-to-Equity Ratio

1.10

means it relies more on debt, which can increase financial risk.

Free cash flow per share

0.56

is a measure of a company's financial flexibility that is determined by dividing free cash flow by the total number of shares outstanding.

Dividend payout ratio

17.54 %

indicates that the company is retaining a large portion of its profits to reinvest in growth

Earnings per share

Loading data...

No data available.

Financials

Piotroski score
5 indicates moderate financial health
Altman score
-3.21 indicates a high risk of bankruptcy
Loading data...

No data available.

Cash / Debt

Cash Ratio
2.86 indicates that the company has sufficient cash to cover its short-term debts
Debt Ratio
0.46 indicates that the company uses little debt to finance its assets, suggesting good financial stability
Loading data...

No data available.

Free Cash Flow

Loading data...

No data available.

Earnings Per Share (annual)

Loading data...

No data available.

Sales

Loading data...

No data available.